This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutInfliximabWhat is infliximabInflammatory Bowel DiseaseMaximising patient outcomes with IBDBiosimilarsWhat is a biosimilarFuture of biosimilarsBiologic switchingINFLECTRA® Introducing INFLECTRA® Position statementsECCOEULARESPGHANDosing & safetyDosingIV dosingAdministration & storageAdministrationStorageSafety informationImportant safety informationConsiderations for SwitchingSwitching to InflectraSafety informationImportant safety informationSafety informationSafety informationClinical evidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceReal-world experienceSummary: real-world evidenceSupporting ResourcesVideosMaterialsPatient Support


Inflectra®(infliximab) Prescribing Information. Adverse events reporting information can be found at the bottom of the page.

 

What is a Biosimilar

A biosimilar is a biologic product that is approved based on a demonstration that shows that it is highly similar to an approved biologic product, known as the reference product.1-3
 

Biosimilars are developed to be highly similar to the reference product with no clinically meaningful differences in terms of quality, efficacy and safety.1-3
 

Biosimilars can support a more sustainable healthcare system,4-7 expanding treatment options and enabling cost savings8 without compromising safety or efficacy.1-3,9

Potential Benefits of Biosimilars

Potential benefits of biosimilars for patients, payers and providers include:4-6
 

 Header

‘’Biosimilars have the potential to offer the NHS considerable cost savings especially as biological medicines are often expensive and are often used to treat long-term conditions.10’’ - NICE

Return to our Inflectra homepage to explore more about Infliximab 

KickerHeader of this CTA card goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…

Button

References:

1.Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD: FDA; 2015.
2. McCamish M, Woollett G. Worldwide Experience with Biosimilar Development. MAbs. 2011. 3(2):209-217.
3. Kay J, Feagen BG, Guirguis MS, et al. Health Canada/BIOTECanada Summit on Regulatory and Clinical Topics Related to Subsequent Entry Biologics (biosimilars). Biologicals. 2012. 40(6):517-527.
4. Scheinberg MA, Kay J. The Advent of Biosimilar Therapies in Rheumatology—“O Brave New World.” Nat Rev Rheumatol. 2012. 8(7):430-436.
5.Henry D, Taylor C. Pharmacoeconomics of Cancer Therapies: Considerations with the Introduction of Biosimilars. Semin Oncol. 2014. 41(suppl 3):S13-S20.#
6.Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and Biosimilars in Psoriasis: What the Dermatologist Needs to Know. J Am Acad Dermatol. 2012. 66(2):317-322.
7.Blackstone EA, Fuhr Jr JP. Biologics & Biosimilars: The Possibility of Encouraging Innovation And Competition. The SciTech Lawyer, 2015.
8.Haustein R, et al. GaBi Journal. 2012. 1(3-4):120-126.
9. The Biosimilars Forum. Biosimilars Overview. 2017
10.NICE. Biosimilar Medicines. [online]. 2016 [Accessed March 2021]. Available from: https://www.nice.org.uk/advice/ktt15/resources/biosimilar-medicines-pdf-58757954414533.Biosimilars
Browse additional content and information that may be of interest to you  Explore MoreLoading
Learn about the evidence supporting the use of Inflectra.
PP-IFA-GBR-0607. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​